StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for SRZN yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-20 | $25.00 | $27.05 | +8.20% | 0.1M |
| 05-21 | $26.70 | $27.09 | +1.46% | 0.0M |
| 05-22 | $26.87 | $26.37 | -1.86% | 0.1M |
| 05-26 | $26.54 | $26.17 | -1.39% | 0.1M |
| 05-27 | $25.99 | $26.68 | +2.65% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $5.00M | $3.48M | $2.95M | $1.97M |
Operating Income | $-10.46M | $-42.09M | $-29.45M | $-18.57M |
Net Income | $-127.50M | $-242.03M | $-58.87M | $12.78M |
EPS (Diluted) | $-11.65 | $-32.37 | $-8.49 | $0.85 |
Total Assets | $120.71M | $98.73M | $94.05M | $102.70M |
Total Liabilities | $398.86M | $286.49M | $117.56M | $55.58M |
Cash & Equivalents | $106.91M | $89.25M | $81.33M | $90.39M |
Free Cash Flow OCF − CapEx | $-12.62M | $-30.37M | $-24.50M | $-15.44M |
Shares Outstanding | 11.49M | 9.78M | 8.57M | 8.57M |